AbbVie Close to $10.9B Acquisition of Apogee Therapeutics
AbbVie is reportedly nearing a $10.9 billion deal to acquire Apogee Therapeutics, a move that would expand the pharma giant's pipeline.
If you've been watching the pharmaceutical M&A space, here's a big one to add to your radar: AbbVie is reportedly close to sealing a $10.9 billion deal to acquire Apogee Therapeutics, according to reports cited by SeekingAlpha. That's a serious chunk of change, even for a company of AbbVie's scale.
AbbVie, best known as the maker of blockbuster drugs like Humira, has been actively scouting acquisition targets as it works to diversify its revenue streams and build out its pipeline for the years ahead. A deal of this size signals the company isn't shy about writing big checks when it sees strategic value — and Apogee Therapeutics appears to fit that bill.
Read more 7 Best QuickBooks Alternatives for Small Businesses in 2025 →
Apogee Therapeutics is a clinical-stage biotech focused on developing treatments for immunological and inflammatory diseases, a therapeutic area where AbbVie already has deep roots. Bringing Apogee into the fold could give AbbVie a meaningful boost in next-generation drug candidates, potentially helping it stay competitive as older drugs face patent cliffs and generic competition.
For everyday investors, a deal like this is worth paying attention to for a couple of reasons. First, acquisition premiums often send the target company's stock surging — so biotech watchers who spotted Apogee early may be sitting pretty. Second, large acquisitions can sometimes weigh on the acquiring company's stock short-term, as Wall Street digests the cost and integration risk. Whether $10.9 billion turns out to be a bargain or an overpay will likely depend on how Apogee's pipeline performs in future clinical trials.
No deal is official until the ink dries, and terms could still change, so keep an eye on further developments. Continue reading at SeekingAlpha.
